Arrowhead Research Corporation — Form 10-Q Summary
Business context and reporting period. The filing covers the fiscal third quarter and nine months ended June 30, 2014. Arrowhead develops targeted RNA interference (RNAi) therapeutics using its Dynamic Polyconjugate delivery platform. Its pipeline included ARC-520 for chronic hepatitis B, newly announced ARC-AAT for Alpha-1 antitrypsin deficiency-related liver disease, and partner-based obesity and oncology programs. The filing identifies the registrant as Arrowhead Research Corporation.
Financial performance and position
| Metric | Three months ended June 30, 2014 | Nine months ended June 30, 2014 |
|---|---|---|
| Revenue | $43,750 | $131,250 |
| Operating expenses | $12.7 million | $31.1 million |
| Operating loss | $12.7 million | $30.9 million |
| Net loss attributable to Arrowhead | $11.6 million | $36.2 million |
| Loss per share, basic and diluted | $0.22 | $0.81 |
| Cash used in operating activities | Not separately provided | $24.5 million |
- At June 30, 2014, cash and cash equivalents were $138.3 million; held-to-maturity commercial notes totaled $50.1 million, comprising $23.8 million short-term and $26.3 million long-term. Management described cash and liquid investments as $188.5 million.
- Total assets were $196.6 million, total liabilities $10.8 million, and stockholders’ equity $185.8 million.
- Debt was limited: notes payable were $50,000 current, with no long-term notes payable. Capital lease obligations totaled approximately $1.0 million ($213,000 current and $812,000 long-term). The balance sheet also reported $4.0 million of derivative liabilities and $1.8 million of other non-current liabilities.
- Nine-month cash flow included $41.0 million used in investing activities, largely net purchases of fixed-income investments, and $184.8 million provided by financing activities. Cash increased $119.2 million to $138.3 million.
- Operating margin was not meaningful given minimal revenue and the company’s development-stage operations; the filing does not present a gross margin measure.
Material changes versus the prior comparable period
- Third-quarter revenue was unchanged at $43,750; nine-month revenue fell to $131,250 from $246,516, partly because the prior period included $115,266 of non-recurring services revenue.
- Third-quarter operating expenses rose 98% to $12.7 million; nine-month operating expenses rose 84% to $31.1 million. R&D expense increased 264% for the quarter and 170% for the nine-month period, principally reflecting drug manufacturing, toxicology/efficacy studies, clinical activity, and expanded research staffing.
- Nine-month net loss attributable to Arrowhead increased to $36.2 million from $17.5 million. However, loss per share improved to $0.81 from $0.92, as weighted-average shares increased substantially following equity issuances.
- The company raised approximately $172.6 million net through October 2013 and February 2014 equity financings and received $12.4 million from warrant and option exercises. Common shares outstanding increased to 52.9 million from 32.5 million at September 30, 2013, with additional potential dilution from preferred shares, options, warrants, and restricted stock units.
- Nine-month other expense included a $5.7 million non-cash loss from changes in derivative fair value, compared with a $0.2 million gain in the prior-year period. In the third quarter, derivative remeasurement contributed to a $0.8 million gain.
Outlook, commentary, risks, and unusual items
- Management stated that existing resources were expected to fund operations for the next 12 months and beyond. It also expected continued significant cash needs as R&D and clinical work advanced; manufacturing costs were expected to rise for a larger ARC-520 Phase 2b study anticipated in 2015.
- ARC-520’s Phase 1 healthy-volunteer trial had completed enrollment, with no dose-limiting toxicities or serious adverse events reported to date. A Phase 2a pilot efficacy study in chronic hepatitis B patients began in Hong Kong in March 2014 and was ongoing.
- Calando Pharmaceuticals was deconsolidated in the quarter after control passed to a Chapter 7 bankruptcy trustee. Arrowhead reported $4.5 million owed by Calando, fully reserved, and a separate $1.253 million Calando note payable to another holder. Recovery from asset liquidation was uncertain; Arrowhead did not expect its ownership to yield a return of capital.
- Valuation of derivative and contingent consideration liabilities relies on Level 3 inputs and management assumptions; changes can materially affect reported earnings. The $1.595 million contingent consideration liability was unchanged during the nine months.
- The company reported no material litigation, no material changes to previously disclosed risk factors, effective disclosure controls, and no material change in internal control over financial reporting.
Key facts for investors to verify
- Progress, safety, efficacy, timing, and funding needs for ARC-520 and the planned Phase 2b study, as well as development plans for ARC-AAT.
- Actual operating cash burn and investment maturities relative to management’s liquidity outlook, including the company’s expectation to hold bonds to maturity.
- Potential dilution from outstanding preferred stock and equity awards, and the effect of future financing needs.
- Calando bankruptcy distributions and any recovery on Arrowhead’s reserved receivables and advances.
- Derivative-liability valuation and the effect of stock-price changes on non-cash earnings volatility.